NTRA Natera Inc
Company Analysis
Latest News
🔴 Natera is trading 14.2% down after quarterly loss misses estimates
Natera is trading at $320.18, down 14.20%, after its $0.42-per-share quarterly loss missed analysts’ $0.27 estimate. - November 5 results showed $794 million...
Natera Beat on Revenue and Raised Guidance — So Why Did the Stock Lose $6 Billion in a Day?
Shares of genetic testing company Natera cratered 12.6% to $318.00 after the company posted a third-quarter loss far wider than Wall Street expected — even as...
🔴 Natera is trading 12.6% down in pre-market after a wider-than-expected GAAP loss
Natera is trading at $318.00 (-12.58%) in pre-market after reporting a wider-than-expected GAAP loss. - Q3 revenue was $794 million, beating estimates, and...
Natera's third quarter revenue of $794M beat estimates by 13% as full year guidance was raised
Natera reported third quarter 2026 revenues that significantly exceeded expectations, fueled by 61% growth in oncology test volumes and improved average...
🔴 Natera is trading 6% down today
Natera is trading 6.03% lower at $367.44, with no verified company-specific catalyst identified. - Third-quarter results are scheduled for after the market...
🔴 Natera is trading 5% down in pre-market — no verified catalyst identified
Natera is trading 4.87% down at $372.00, with no verified company-specific catalyst identified for the pre-market decline. - Natera is scheduled to report...
🔴 Natera is trading 4.6% down — no verified catalyst identified
Natera is trading 4.6% down at $370.73 on November 4, 2026, with no clear company-specific announcement or verified catalyst identified. - Natera is scheduled...
Natera Inc Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026
Natera is projected to report Q3 2026 revenue of $702.9 million and a narrowed loss per share of $0.28, as the stock trades around $388.78 against a consensus...
🔴 Natera is trading 4.2% down
Natera is trading at $396.90, down 4.20%, with no clear company-specific announcement explaining the November 2 decline in available coverage. - Natera’s Q3...
🔴 Natera is trading 5% down amid broad market selloff
Natera is trading 5.22% down at $413.24 on October 30, 2026, amid a broad market selloff. - Friday, the S&P 500 fell 1.2% and the Nasdaq Composite fell 2.2%,...
🟢 Natera is trading 4.2% up today, outpacing biotech sector gains
Natera is trading 4.2% up at $428.12 on October 28, 2026, with no clearly attributable company-specific catalyst identified for the move. - XBI is up 2.18%,...
🔴 Natera is trading 4.6% down today amid broader risk-off trading
Natera is trading 4.55% lower at $394.56 as of 11:29 a.m. ET on October 22, 2026, with broader risk-off trading the likeliest context; no clear...
🔴 Natera is trading 19.04% down in after-hours trading
Natera is trading 19.04% down at $318.53 after-hours, with no verified late-breaking company announcement explaining the drop. - It closed the October 16...
🔴 Natera is trading 5% down today as biotech lags broader indexes
Natera is trading at $404.91, down 4.87%, amid biotech-sector pressure; no specific catalyst directly explaining the decline was found. - The sector ETF fell...
Natera Launches Major Breast Cancer Trial to Guide Treatment Decisions
Natera launched a Phase III clinical trial. It partners with Alliance Foundation Trials (AFT) and Genentech. The trial evaluates a new approach for...
🟢 Natera is trading 5.3% up in pre-market
Natera is trading 5.27% higher at $430.00, with no fresh company-specific catalyst confirmed for October 2, 2026. - The previously reported Japan regulatory...
🟢 Natera is trading 5.5% up in pre-market; no fresh catalyst confirmed
Natera is trading 5.51% up in pre-market at $436.10 on October 1, versus its September 30 close of $413.31, with no clearly confirmed fresh catalyst. - The...
🟢 Natera is trading 5% up in pre-market after Japan approved Signatera for muscle-invasive bladder cancer
Natera is trading 5.03% higher at $429.34 as investors respond to Japan’s September 22 approval of Signatera as a companion diagnostic for muscle-invasive...
🟢 Natera is trading 4.3% up today on Japan's Signatera companion-diagnostic approval
Natera is trading 4.3% up at $407.55 as investors focus on Signatera’s regulatory and clinical progress. - Japan approved Signatera as a companion diagnostic...
🔴 Natera is trading 13.65% down in after-hours trading as Nasdaq and S&P 500 fall
Natera is trading 13.65% lower at $337.46 in after-hours trading, with the decline appearing primarily tied to risk-off market conditions. - Shares closed at...